Idexx Laboratories (IDXX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$535.38+1.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · IDXX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 35.9% |
| Our one-year growth estimate | diamond | 9.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 26.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
IDXX — President transition
Dated 2026-03-26
Executive Vice President, Global Strategy and Commercial — Nimrata Hunt, PhD: Dr. Nimrata Hunt is departing from her role with significant severance benefits.
Why it matters: Earnings results will show if the company meets growth expectations. It can shift investor views.
Watch forQ2 earnings beat analyst expectations. Revenue grew by more than 10%.
Also watch forQ2 earnings miss expectations with revenue growth below 5%.
Why it matters: Many instrument placements show strong demand and success in innovation. This is key for growth.
Supportive ifIn Q3, instrument placements went over 1,600 units.
Worry ifIn Q3, instrument placements are less than 1,200 units.
Why it matters: The new CEO may change IDEXX's strategy and how it operates.
Watch forPositive comments from stakeholders on the new CEO's strategic vision by Q3.
Also watch forConcerns raised by stakeholders about the new CEO's direction by Q3.
Why it matters: Changes in leadership can change company strategy and performance. Watch this to see future plans.
Watch forGood performance numbers came in after Michael Erickson became CEO.
Also watch forBad performance numbers came in after Michael Erickson became CEO.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$128 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $309 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,134 loss on $10,000 · 31.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Changes in EPS guidance show that management is sure about the financial results.
Supportive ifEPS guidance raised above $14.90 for 2026 in the Q2 earnings report.
Worry ifEPS guidance remains below $14.45 for 2026 in the Q2 earnings report.
Why it matters: High placements of new products indicate strong market acceptance. This can drive future revenue growth.
Supportive ifNew product placements exceed 1,600 in the next quarter.
Worry ifNew product placements fall below 1,600.
Why it matters: Earnings per share growth shows how healthy a company is. Higher EPS means better profits and efficiency.
Supportive ifQ2 2026 EPS reported above $3.47.
Worry ifQ2 2026 EPS reported below $3.08.
Why it matters: Falling below this level could mean weak demand and problems with operations.
Worry ifQ2 revenue growth reported below 8.6% year over year.
Less concerning ifQ2 revenue growth reported above 10.6% year over year.
Why it matters: More revenue guidance shows management believes in growth. This can help how the market sees them.
Supportive if2026 revenue guidance raised above $4,745 million in the next earnings report.
Worry ifRevenue guidance remains at or below $4,700 million in the next earnings report.
Why it matters: The CEO transition could impact company strategy and performance. It is crucial to see how the new leadership affects IDEXX's direction.
Watch forNew CEO Michael Erickson outlines a clear growth strategy in his first public address.
Also watch forNew CEO fails to provide a clear vision or strategy during the transition.
Why it matters: Sustained growth in CAG Diagnostics is key for overall revenue health. It shows strong demand for IDEXX's products.
Supportive ifCAG Diagnostics recurring revenue growth remains above 10% year over year.
Worry ifCAG Diagnostics recurring revenue growth falls below 9% year over year.
Why it matters: Higher EPS guidance shows strong performance and good cost control. This can help investor trust.
Supportive ifManagement expects 2026 EPS to be over $14.94.
Worry ifEPS guidance remains at or below $14.94.
Why it matters: Going above this level shows higher demand and better efficiency.
Supportive ifRevenue growth guidance exceeds 10.3% for 2026.
Worry ifRevenue growth guidance stays at or below 10.3%.
Why it matters: More placements indicate strong market acceptance and can drive future revenue growth.
Supportive ifIDEXX inVue Dx placements exceed 1,600 in the next quarter.
Worry ifIDEXX inVue Dx placements fall below 1,600 in the next quarter.